Abstracts tagged "Disease Activity"

Abstract Number: 0485 • ACR Convergence 2024
Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort
Tahzeeb Fatima¹, Yuan Zhang², Georgios Vasileiadis², Araz Rawshani², Ronald Van Vollenhoven³, Jon Lampa⁴, Bjorn Gudbjornsson⁵, Espen Haavardsholm⁶, Dan Nordstrom⁷, Gerdur Gröndal⁵, Kim Hørslev-Petersen⁸, Kristina Lend⁹, Marte Heiberg¹⁰, Merete Hetland¹¹, Michael Nurmohamed¹², Mikkel Ostergaard¹³, Tillmann Uhlig⁶, Tuulikki Sokka-Isler¹⁴, Anna Rudin¹⁵ and Cristina Maglio², ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Gothenburg, Sweden, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Karolinska University Hospital, Hässelby, Sweden, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University Hospital of Southern Denmark, Sønderborg, Denmark, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰Diakonhjemmet Hospital, Oslo, Oslo, Norway, ¹¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹⁴Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁵Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Leonie Middelink¹, Annemarie Kip², Maarten van der Linden³, Sangeeta Kumari², Stephanie van Dalen², Josephine Stein⁴, Tirza Bruurmijn², Martyn Foster⁵, Peter van Zandvoort², Patrick Round², Eric Meldrum², Helmuth van Es² and Renato Chirivi², ¹Citryll, Oss, Noord-Brabant, Netherlands, ²Citryll BV, Oss, Noord-Brabant, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴Citryll BV, Oss, Noord-Holland, Netherlands, ⁵Experimental Pathology Consultancy, Benfleet, United Kingdom
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…
Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Xenofon Baraliakos¹, Victoria Navarro Compán², Elena Nikiphorou³, Thao Pham⁴, Francesco Ciccia⁵, Megan Hughes⁶, Bruno Kranz⁶, Anna Jus⁷, Chris Watson⁷, Jo Lowe⁸ and Sofia Ramiro⁹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³King's College London, London, United Kingdom, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Alfasigma S.p.A., Bologna, Italy, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1477 • ACR Convergence 2024
Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
Alice Gottlieb¹, Elena Muensterman², Alan Kivitz³, Eva Dokoupilova⁴, Apinya Lertratanakul⁵, Ting Hong⁵, Jingjing Chen⁵ and Xenofon Baraliakos⁶, ¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ²Takeda Development Center Americas, Cambridge, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial in patients with active psoriatic arthritis…
Abstract Number: 1769 • ACR Convergence 2024
Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Ujana Zajmi¹, Megan Darrell¹, Amy Kaneshiro¹, Adeline Chin¹, Adriana Jesus², Stephen Brooks¹, Raphaela Goldbach-Mansky², Lisa Rider³ and Hanna Kim⁴, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NIAD, Bethesda, MD, ³NIEHS, NIH, Garrett Park, MD, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Myositis-specific autoantibody (MSA) subgroups define phenotypes associated with specific clinical traits and outcomes within JDM, a clinically heterogeneous autoimmune disease. The pathogenesis of JDM…
Abstract Number: 2214 • ACR Convergence 2024
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
Irtza Badar¹ and Martin Bergman², ¹Mercy Catholic Medical Center, Philadelphia, PA, ²self, Beach Haven, NJ
Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
Abstract Number: 0493 • ACR Convergence 2024
An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs
Cinja Koller¹, Marc Blanchard², Jules Maglione³, Patrick Hermann⁴ and Thomas Huegle³, ¹Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Perroy, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴Lausanne University Hospital, Lausanne, Vaud, Switzerland
Background/Purpose: Advancement in technology has fostered Remote Patient Monitoring (RPM), but it is mainly subjectively measured by patient reported outcomes or non-specifically via wearable data.…
Abstract Number: 0584 • ACR Convergence 2024
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Alexis Ogdie¹, Nicole Middaugh², Taylor Blachley², Tran Bourgeois³, You-Li Ling⁴, Rajiv Mundayat⁴, Lara Fallon⁵, Karim Masri⁶ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Real-world (RW) data on the effectiveness of tofacitinib in patients (pts) with PsA are limited. This study summarized disease activity and pt‑reported outcome measures…
Abstract Number: 0802 • ACR Convergence 2024
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Xiaosong Wang⁴, Misti Paudel⁵, Emily Kowalski³, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni³, Caleb Bolden⁶, Tina Mahajan⁷, Erica Mulcaire-Jones⁸, Neda Kortam⁸, Pierre-Antoine Juge⁹, Tracy J Doyle¹⁰, Zachary Wallace¹¹, Marcy Bolster⁶, Kevin Deane¹², Dinesh Khanna⁸, Bryant England⁷ and Jeffrey Sparks¹³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Michigan, Ann Arbor, MI, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital, West Roxbury, MA, ¹¹Massachusetts General Hospital, Newton, MA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…

« Previous Page
1
…
3
4
5
6
7
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].